Types of application for marketing authorisations (legal basis of applications)

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has released comprehensive guidance regarding the legal requirements for marketing authorisation (MA) applications in the United Kingdom, effective January 1, 2025. Governed by the Human Medicines Regulations 2012 (HMRs), the document outlines the various pathways companies must follow to license medicinal products. These pathways range from full applications (Regulation 50), requiring complete clinical and pharmaceutical data, to simplified routes for generic, hybrid, and biosimilar products (Regulations 51B, 52B, and 53B). Abridged applications allow companies to omit certain data by referencing a product already authorised for at least eight years, provided they prove bioequivalence. The guidance also covers specific registrations for traditional herbal medicines and homeopathic products, which are based on historical use and simplified safety requirements. Key regulatory standards include an eight-year data protection period and a ten-year market exclusivity period for new medicines, with potential one-year extensions for significant new therapeutic uses. As this is a prospective guidance document rather than a post-inspection report, there are no specific company violations or inspection dates recorded. Instead, the MHRA requires all applicants to select the correct legal basis for their submission to ensure the documentation provided is sufficient to prove product safety and efficacy. Failure to align applications with the specific HMR regulations may result in the rejection of the marketing authorisation.